Portfolio Companies News
July 13, 2018HealthCap makes 112th investment as...
Funds to be used to continue the clinical development of sevuparin for sickle cell disease STOCKHOLM, SWEDEN – 13 July 2018: Modus Therapeutics AB, a company developing innovative treatments in high unmet medical need disease areas with a focus on sickle cell disease (SCD), announces that it has ... read more
July 12, 2018Altimmune Restructures Financing Ag...
GAITHERSBURG, Md., July 12, 2018 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company focused on preventing infectious diseases, today announced it has entered into agreements with substantially all of the remaining investors in its Series B Financing to ... read more
July 12, 2018Targovax and SOTIO announce first p...
Oslo, Norway, 12 July 2018 - Targovax ASA (OSE: TRVX), a clinical stage company focused on developing and commercializing immune activators to target hard to treat solid tumors, and SOTIO, a biotechnology company owned by the PPF Group, announce that the first patient has been dosed with ONCOS-102 i... read more
July 12, 2018New Preclinical Results on Onxeo’...
AsiDNA™ combined with olaparib* more than doubled the complete response rate observed with olaparib alone in an in vivo model of triple negative breast cancer resistant to PARP inhibitors AsiDNA™ combined with olaparib inhibited tumor growth in an in vivo model of ovarian cancer resistant... read more
July 12, 2018Interim Report Q2 2018
Zubsolv® continues its strong performance Q2 2018 highlights Total net revenues of SEK 199.7 million (159.1), up 25.5 percent from Q2 previous year Zubsolv US net revenue of SEK 158.4 million (124.1), up 27.6 percent in SEK and 29.8 percent in local currency compared to the same period l... read more
May 02, 2018Q1 2018 General Market Overview
Since the start in 1996, HealthCap funds have invested in 112 portfolio companies.
41 of the portfolio companies have been taken public on nine different markets.
25 of the portfolio companies’ pharmaceutical products have been approved for marketing.
Since the start in 1996, HealthCap has helped build 7 companies with a valuation of USD 1 billion or more and 35 companies with a valuation of SEK 1 billion or more.